Getting to the heart of Boston Scientific’s peripheral business; How Hologic sees trials changing
Jeff Mirviss, executive vice president of Boston Scientific’s peripheral business, explains why the specialty’s name doesn’t really reflect the importance of arteries, veins and other “highways” that his business group is addressing. Mirviss explains where the peripheral business is headed, and why Boston Scientific is uniquely positioned to address the business. He also shares lessons learned over his 20-plus years at Boston Scientific including the challenges presented by the Guidant acquisition and the new spirit infused by CEO Michael Mahoney. We also speak with Eric Kolodziej, corporat…
